Synaps

Developing novel photodynamic therapies for neurosurgery

Synaps
  • About
    • Overview
    • Partnership >
      • Onco-THAI Inserm U1189
      • University of Lille
      • Lille University Hospital
      • Inserm
      • ECRIN
      • Leitat Technological Center
      • IDDI
      • Medical University of Graz
      • OP2
      • Erasme Hospital
  • Research
    • Overview
    • Clinical trial
    • Publications
  • Medical information
    • Overview
    • Glioblastoma
    • PhotoDynamic Therapies
  • News
  • Contact

  • About
    • Overview
    • Partnership >
      • Onco-THAI Inserm U1189
      • University of Lille
      • Lille University Hospital
      • Inserm
      • ECRIN
      • Leitat Technological Center
      • IDDI
      • Medical University of Graz
      • OP2
      • Erasme Hospital
  • Research
    • Overview
    • Clinical trial
    • Publications
  • Medical information
    • Overview
    • Glioblastoma
    • PhotoDynamic Therapies
  • News
  • Contact

News

Synaps is strengthening with new partners

10/10/2016

 
Today, Synaps is supported by different partners involving Clinical, Academic and SMEs groups. Together, basic scientists, neurosurgeons,  SMEs are building capacities to develop a new treatment modality for GBM relying on 5-aminolevulinic acid (5-ALA). 
Facebook LinkedIn Twitter

Synaps proposes a seamless treatment strategy based on intraoperative photodynamic therapy (PDT) to improve local control, and fully embeddable into the current standard of care. SYNAPS is coordinated by University of Lille - ONCO-Thai lab and gathers partners with large experience in i) clinical trial design (IDDI has provided biostatistical and data-management services for 340 clinical trials over the past 5 years, ECRIN is the dedicated European Infrastructure), ii) in rare diseases drug development (OP2 has been managing several clinical trials in rare disorders including a phase 3 trial with 10 centres in the EU and the US), iii) in medical device (INTERMEDIC has developed a dedicated LASER technology for a phase 3 clinical trial on vascular-targeted PDT) iv) "omics" (Oncoradiomics and LEITAT). The involvement of Clinical teams  (University Hospital of Lille, ULB-ERASME, Medical University of Gräz) in large-scale clinical trials on new GBM treatments is of importance to ensure the success in evaluating this new treatment. 

Comments are closed.
Université Lille 2
Onco Thai
Inserm
CHRU Lille
Picture
 Legal notice - Credits